Previous close | 1,641.50 |
Open | 1,643.00 |
Bid | 1,642.50 x 0 |
Ask | 1,642.00 x 0 |
Day's range | 1,626.00 - 1,656.00 |
52-week range | 1,261.00 - 1,656.00 |
Volume | |
Avg. volume | 330,070 |
Market cap | 2.552T |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 37.32 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 30.74 (1.87%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | N/A |
AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced the acceptance of an abstract related to the clinical study of C-CAR031, an autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) therapy, in hepatocellular carcinoma (HCC) for oral presentation at the American Society of Clinical Oncology (ASCO) Annual M
CAMBRIDGE, United Kingdom, April 25, 2024--Q1 Earnings Release (25 April 2024)
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).